# Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer

> **NCT07085273** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First Affiliated Hospital of Zhengzhou University** · enrollment: 33 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Irinotecan Liposomal

## Key facts

- **NCT ID:** NCT07085273
- **Lead sponsor:** The First Affiliated Hospital of Zhengzhou University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-06-30
- **Target enrollment:** 33 (ESTIMATED)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07085273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07085273, "Irinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07085273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*